V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Gilead Sciences Executive Compensation (FY25)

GILD · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 4, 2026
343 figures on this page: 334 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
Companies named in the disclosed peer group include AbbVie Inc., Amgen Inc., Biogen Inc., Bristol Myers Squibb Company and Eli Lilly and Company, among others. Separately, Daniel O'Day, Chairman and Chief Executive Officer, received $28,437,198 in total compensation for fiscal 2025, and compared with the $23,689,392 reported for fiscal 2024, O'Day's total was 20.0% higher, while the disclosed chief executive pay ratio for fiscal 2025 is 119:1, against median employee compensation of $238,979. The say-on-pay proposal drew 92.2% of votes cast including abstentions in favor at the meeting held April 30, 2026 for fiscal 2025.
Chief executive, fiscal 2025
◇
Daniel O'Day
Latest say-on-pay support
=
April 30, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Daniel O'Day: $23,689,392 → $28,437,198 (20.0% higher)
CEO pay ratio: 97:1 → 119:1 (22.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Gilead Sciences' chief executive and what were they paid?
Daniel O'Day, Chairman and Chief Executive Officer, received $28,437,198 in total compensation for fiscal 2025. Compared with the $23,689,392 reported for fiscal 2024, O'Day's total was 20.0% higher.
What was Gilead Sciences' say-on-pay result?
The say-on-pay proposal drew 92.2% of votes cast including abstentions in favor at the meeting held April 30, 2026 for fiscal 2025.
Which companies are in Gilead Sciences' peer group?
Companies named in the disclosed peer group include AbbVie Inc., Amgen Inc., Biogen Inc., Bristol Myers Squibb Company and Eli Lilly and Company, among others.
What is Gilead Sciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 119:1, against median employee compensation of $238,979.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel O'Day
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel O'Day
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Johanna Mercier
Chief Commercial Officer
◇—◇◇◇—◇◇
Merdad Parsey
Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Dickinson
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel O'Day
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Johanna Mercier
Chief Commercial Officer
◇—◇◇◇—◇◇
Merdad Parsey
Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Dickinson
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel O'Day
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Dietmar Berger
Chief Medical Officer
◇◇◇◇◇—◇◇
Johanna Mercier
Chief Commercial and Corporate Affairs Officer
◇—◇◇◇—◇◇
Andrew Dickinson
Chief Financial Officer
◇—◇◇◇—◇◇
Deborah Telman
Former Executive Vice President, Corporate Affairs and General Counsel
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew DickinsonPerformance Share◇—————◇
Andrew DickinsonPerformance Share◇—————◇
Andrew DickinsonPerformance Share◇—————◇
Andrew DickinsonRSU◇——◇——◇
Andrew DickinsonOPTION◇——◇—◇◇
Daniel O'DayPerformance Share◇◇◇—◇—◇
Daniel O'DayPerformance Share◇◇◇—◇—◇
Daniel O'DayRSU◇——◇——◇
Daniel O'DayPerformance Share◇◇◇—◇—◇
Daniel O'DayOPTION◇——◇—◇◇
Deborah TelmanPerformance Share◇—————◇
Deborah TelmanPerformance Share◇—————◇
Deborah TelmanPerformance Share◇—————◇
Deborah TelmanRSU◇——◇——◇
Deborah TelmanOPTION◇——◇—◇◇
Dietmar BergerPerformance Share◇—————◇
Dietmar BergerRSU◇——◇——◇
Dietmar BergerOPTION◇——◇—◇◇
Dietmar BergerRSU◇——◇——◇
Johanna MercierPerformance Share◇—————◇
Johanna MercierPerformance Share◇—————◇
Johanna MercierPerformance Share◇—————◇
Johanna MercierOPTION◇——◇—◇◇
Johanna MercierRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrew DickinsonPSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Daniel O'DayRSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Johanna MercierOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Dietmar BergerRSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Anthony Welters
Lead independent director
◇◇◇———◇
Kelly A. Kramer
◇◇◇———◇
Sandra J. Horning
◇◇◇——◇◇
Harish M. Manwani
◇◇◇———◇
Jacqueline K. Barton
◇◇◇——◇◇
Ted W. Love
◇◇◇——◇◇
Javier J. Rodriguez
◇◇◇——◇◇
Jeffrey A. Bluestone
◇◇◇——◇◇
Daniel P. O'Day served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Equity is delivered as RSU + Stock Option (50/50).
Stock ownership guideline: 5x annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Amgen Inc. AMGN
  • Biogen Inc. BIIB
  • Bristol Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Johnson & Johnson JNJ
  • Merck & Co., Inc. MRK
  • Pfizer Inc. PFE
  • Regeneron Pharmaceuticals, Inc. REGN
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 30, 2026=◇◇◇
2024May 7, 2025=◇◇◇
2023May 8, 2024=◇◇◇
2022May 3, 2023=◇◇◇
2021May 4, 2022=◇◇◇
2020May 12, 2021=◇◇◇
2019May 6, 2020=◇◇◇
2018May 8, 2019=◇◇◇
2017May 9, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Gilead Sciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Gilead Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Gilead Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Gilead Sciences' disclosed peer group is defensible, who names Gilead Sciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
343 figures on this page: 334 cited to the filing that reported them, 9 calculated from figures it prints.
334 cited to the filing
9 calculated from the filing

Documents cited

  1. 0000882095-26-000008
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001308179-26-000106
    2025 Director Compensation · 2025 Grants of Plan-Based Awards · 2025 Outstanding Equity Awards at Fiscal Year-End · CEO Pay Ratio · and 2 more sections
  3. 0000882095-25-000015
  4. 0001308179-25-000252
    Summary Compensation Table
  5. 0000882095-24-000016
  6. 0001308179-24-000348
    Summary Compensation Table
  7. 0000882095-23-000019
  8. 0001308179-23-000323
  9. 0001104659-22-056435
  10. 0001104659-21-066766
  11. 0001104659-20-058609
  12. 0001104659-19-028215
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001104659-18-032539
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Gilead Sciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/GILD (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Gilead Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Gilead Sciences discloses

The companies named in GILD's own disclosed peer group.

AbbVie Inc.Amgen Inc.Biogen Inc.Bristol Myers Squibb CompanyEli Lilly and CompanyJohnson & JohnsonMerck & Co., Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy